Antagonists to Human and Mouse Vascular Endothelial Growth Factor Receptor 2 Generated by Directed Protein Evolution In Vitro

Chemistry and Biology

Volumn 13, Issue 5, 2006, Pages 549-556

  Getmanova, Elena V ^a   Chen, Yan ^a   Bloom, Laird ^a   Gokemeijer, Jochem ^a   Shamah, Steven ^a   Warikoo, Veena ^a   Wang, Jack ^a   Ling, Vincent ^b   Sun, Lin ^a  

^a Molecular Biology and Genetics   (United States)

^b NONE

Author keywords

CHEMBIO

Indexed keywords

OLIGOPEPTIDE; RECOMBINANT PROTEIN; VASCULOTROPIN RECEPTOR 2;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CELL LINE; CELL PROLIFERATION; CHEMISTRY; DIRECTED MOLECULAR EVOLUTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; MOUSE; MUTAGENESIS; PROTEIN BINDING;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL PROLIFERATION; DIRECTED MOLECULAR EVOLUTION; HUMANS; MICE; MUTAGENESIS; OLIGOPEPTIDES; PROTEIN BINDING; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 33646740974     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2005.12.009     Document Type: Article

References (25)

1. Amstutz P., Forrer P., Zahnd C., and Plückthun A. In vitro display technologies: novel developments and applications. Curr. Opin. Biotechnol. 12 (2001) 400-405
2. Lipovsek D., and Plückthun A. In-vitro protein evolution by ribosome display and mRNA display. J. Immunol. Methods 290 (2004) 51-67
3. Takahashi T.T., Austin R.J., and Roberts R.W. mRNA display: ligand discovery, interaction analysis and beyond. Trends Biochem. Sci. 28 (2003) 159-165
4. Nygren P.A., and Skerra A. Binding proteins from alternative scaffolds. J. Immunol. Methods 290 (2004) 3-28
5. Koide A., Bailey C.W., Huang X., and Koide S. The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284 (1998) 1141-1151
6. Xu L., Aha P., Gu K., Kuimelis R.G., Kurz M., Lam T., Lim A.C., Liu H., Lohse P.A., Sun L., et al. Directed evolution of high-affinity antibody mimics using mRNA display. Chem. Biol. 9 (2002) 933-942
7. Koide A., Abbatiello S., Rothgery L., and Koide S. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc. Natl. Acad. Sci. USA 99 (2002) 1253-1258
8. Karatan E., Merguerian M., Han Z., Scholle M.D., Koide S., and Kay B.K. Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. Chem. Biol. 11 (2004) 835-844
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
10. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. Cancer Sci. 94 (2003) 751-756
11. Folkman J. Endogenous angiogenesis inhibitors. APMIS 112 (2004) 496-507
12. Huang J., Frischer J.S., Serur A., Kadenhe A., Yokoi A., McCrudden K.W., New T., O'Toole K., Zabski S., Rudge J.S., et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. USA 100 (2003) 7785-7790
13. Eskens F.A. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br. J. Cancer 90 (2004) 1-7
14. Midgley R., and Kerr D. Bevacizumab-current status and future directions. Ann. Oncol. 16 (2005) 999-1004
15. Roberts R.W., and Szostak J.W. RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci. USA 94 (1997) 12297-12302
16. Nemoto N., Miyamoto-Sato E., Husimi Y., and Yanagawa H. In vitro virus: bonding of mRNA bearing puromycin at the 3′-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro. FEBS Lett. 414 (1997) 405-408
17. Ferrara N., and Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997) 24-25
18. Main A.L., Harvey T.S., Baron M., Boyd J., and Campbell I.D. The three-dimensional structure of the tenth type III module of fibronectin: an insight into RGD-mediated interactions. Cell 71 (1992) 671-678
19. Claffey K.P., Wilkison W.O., and Spiegelman B.M. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. J. Biol. Chem. 267 (1992) 16317-16322
20. Shima D.T., Kuroki M., Deutsch U., Ng Y.S., Adamis A.P., and D'Amore P.A. The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 271 (1996) 3877-3883
21. Lee J., Gray A., Yuan J., Luoh S., Avraham H., and Wood W.I. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA 93 (1996) 1988-1992
22. Parker M.H., Chen Y., Danehy F., Dufu K., Ekstrom J., Getmanova E., Gokemeijer J., Xu L., and Lipovsek D. Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng. Des. Sel. 18 (2005) 435-444
23. Lu D., Shen J., Vil M.D., Haifan Zhang H., Jimenez X., Bohlen P., Witte L., and Zhu Z. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J. Biol. Chem. 278 (2003) 43496-43507
24. Vartanian J.P., Henry M., and Wain-Hobson S. Hypermutagenic PCR involving all four transitions and a sizeable proportion of transversions. Nucleic Acids Res. 24 (1996) 2627-2631
25. Kurz M., Gu K., and Lohse P.A. Psoralen photo-crosslinked mRNA-puromycin conjugates: a novel template for the rapid and facile preparation of mRNA-protein fusions. Nucleic Acids Res. 28 (2000) E83